Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS), which worsen patients’ health and increase healthcare spending. The aim of this study was to assess the clinical and economic impact of switching from omalizumab (OMA) to mepolizumab (MEP) in patients eligible...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Sci Rep
Главные авторы: Carpagnano, Giovanna Elisiana, Resta, Emanuela, Povero, Massimiliano, Pelaia, Corrado, D’Amato, Mariella, Crimi, Nunzio, Scichilone, Nicola, Scioscia, Giulia, Resta, Onofrio, Calabrese, Cecilia, Pelaia, Girolamo, Barbaro, Maria Pia Foschino
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2021
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7943587/
https://ncbi.nlm.nih.gov/pubmed/33750842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-84895-2
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы